143 related articles for article (PubMed ID: 15280408)
21. Assessment of cell proliferation in normal and pathological bone marrow biopsies: a study using double sequential immunophenotyping on paraffin sections.
Pellegrini W; Facchetti F; Marocolo D; Salvi L; Capucci A; Tironi A; Rossi G
Histopathology; 1995 Nov; 27(5):397-405. PubMed ID: 8575729
[TBL] [Abstract][Full Text] [Related]
22. Assessment of bone marrow fibrosis and angiogenesis in monitoring patients with multiple myeloma.
Babarović E; Valković T; Štifter S; Budisavljević I; Seili-Bekafigo I; Duletić-Načinović A; Lučin K; Jonjić N
Am J Clin Pathol; 2012 Jun; 137(6):870-8. PubMed ID: 22586045
[TBL] [Abstract][Full Text] [Related]
23. A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients.
Kuranda K; Berthon C; Dupont C; Wolowiec D; Leleu X; Polakowska R; Jouy N; Quesnel B
Exp Hematol; 2010 Feb; 38(2):124-31. PubMed ID: 19948206
[TBL] [Abstract][Full Text] [Related]
24. Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma.
Pappa CA; Tsirakis G; Kanellou P; Kaparou M; Stratinaki M; Xekalou A; Alegakis A; Boula A; Stathopoulos EN; Alexandrakis MG
Cytokine; 2011 Dec; 56(3):616-20. PubMed ID: 21940178
[TBL] [Abstract][Full Text] [Related]
25. Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes.
Lundberg LG; Hellström-Lindberg E; Kanter-Lewensohn L; Lerner R; Palmblad J
Leuk Res; 2006 Mar; 30(3):247-53. PubMed ID: 16099505
[TBL] [Abstract][Full Text] [Related]
26. Neovascularization of bone marrow in patients with diffuse multiple myeloma: a correlative study of magnetic resonance imaging and histopathologic findings.
Baur A; Bartl R; Pellengahr C; Baltin V; Reiser M
Cancer; 2004 Dec; 101(11):2599-604. PubMed ID: 15503306
[TBL] [Abstract][Full Text] [Related]
27. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.
Rajkumar SV; Mesa RA; Fonseca R; Schroeder G; Plevak MF; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Gertz MA; Kyle RA; Russell SJ; Greipp PR
Clin Cancer Res; 2002 Jul; 8(7):2210-6. PubMed ID: 12114422
[TBL] [Abstract][Full Text] [Related]
28. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.
Martín P; Santón A; Bellas C
Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904
[TBL] [Abstract][Full Text] [Related]
29. Angiogenesis and the role of bone marrow endothelial cells in haematological malignancies.
De Raeve H; Van Marck E; Van Camp B; Vanderkerken K
Histol Histopathol; 2004 Jul; 19(3):935-50. PubMed ID: 15168356
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid leukemia: a morphometric study.
Korkolopoulou P; Viniou N; Kavantzas N; Patsouris E; Thymara I; Pavlopoulos PM; Terpos E; Stamatopoulos K; Plata E; Anargyrou K; Androulaki A; Davaris P; Yataganas X
Leukemia; 2003 Jan; 17(1):89-97. PubMed ID: 12529665
[TBL] [Abstract][Full Text] [Related]
31. Clinical and histopathological study of angiogenesis in multiple myeloma.
Marisavljevic D; Markovic O; Cemerikic V; Babic D
J BUON; 2011; 16(1):98-103. PubMed ID: 21674857
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of telomerase activity in multiple myeloma.
Shiratsuchi M; Muta K; Abe Y; Motomura S; Taguchi F; Takatsuki H; Uike N; Umemura T; Nawata H; Nishimura J
Cancer; 2002 Apr; 94(8):2232-8. PubMed ID: 12001122
[TBL] [Abstract][Full Text] [Related]
33. [Bone marrow angiogenesis in patients with multiple myeloma as a marker of biological behaviour].
Tichá V; Tichý M; Scudla V; Kolár Z
Cesk Patol; 2006 Jul; 42(3):115-9. PubMed ID: 16955557
[TBL] [Abstract][Full Text] [Related]
34. The expression of the multidrug transporter P-170 glycoprotein in remission phase is associated with early and resistant relapse in multiple myeloma.
Musto P; Lombardi G; Matera R; Carotenuto M
Haematologica; 1991; 76(6):513-6. PubMed ID: 1687943
[TBL] [Abstract][Full Text] [Related]
35. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.
Nefedova Y; Landowski TH; Dalton WS
Leukemia; 2003 Jun; 17(6):1175-82. PubMed ID: 12764386
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of vascular endothelial growth factor immunoexpression in the context of adverse standard prognostic factors in multiple myeloma.
Ribas C; Colleoni GW; Silva MR; Carregoza MJ; Bordin JO
Eur J Haematol; 2004 Nov; 73(5):311-7. PubMed ID: 15458509
[TBL] [Abstract][Full Text] [Related]
37. Bone marrow angiogenesis and proliferation in B-cell chronic lymphocytic leukemia.
Wolowiec D; Wozniak Z; Potoczek S; Ganczarski G; Wrobel T; Kuliczkowski K; Frydecka I; Jeleń M
Anal Quant Cytol Histol; 2004 Oct; 26(5):263-70. PubMed ID: 15560532
[TBL] [Abstract][Full Text] [Related]
38. Mast cells influence the proliferation rate of myeloma plasma cells.
Pappa CA; Tsirakis G; Stavroulaki E; Kokonozaki M; Xekalou A; Konsolas I; Alexandrakis MG
Cancer Invest; 2015 Apr; 33(4):137-41. PubMed ID: 25738408
[TBL] [Abstract][Full Text] [Related]
39. Serum angiogenin is not elevated in patients with early B-cell chronic lymphocytic leukemia but is prognostic factor for disease progression.
Molica S; Vitelli G; Levato D; Giannarelli D; Vacca A; Cuneo A; Ribatti D; Digiesi G
Eur J Haematol; 2004 Jul; 73(1):36-42. PubMed ID: 15182336
[TBL] [Abstract][Full Text] [Related]
40. [Determination proliferative activity of myeloma cells in histologic material].
Fabian P; Kren L; Nenutil R
Cesk Patol; 2004 Apr; 40(2):46-9. PubMed ID: 15233016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
